日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Multiple Endocrinology Immune-Related Adverse Events (irAEs) Related to Pembrolizumab as Neoadjuvant Treatment in Two Cases of TNBC Patients: Case Reports and Literature Review

两例三阴性乳腺癌患者接受帕博利珠单抗新辅助治疗后出现多种内分泌免疫相关不良事件(irAEs):病例报告及文献综述

Ardakani, Khashayar Yazdanpanah; Passarella, Gaia; Lania, Andrea Gerardo Antonio; Clementi, Thoma Dario; Fanti, Alessandro; Pepe, Francesca Fulvia; Capici, Serena; Cazzaniga, Marina Elena

Metronomic (mCHT) vs standard (sCHT) chemotherapy as first-line treatment in HR+/HER2- Metastatic Breast Cancer (MBC) patients following failure of endocrine treatments. The matched control VICTOR-15 study

节拍式化疗(mCHT)与标准化疗(sCHT)作为HR+/HER2-转移性乳腺癌(MBC)患者内分泌治疗失败后的一线治疗方案的比较。VICTOR-15匹配对照研究

Cazzaniga, Marina Elena; Galimberti, Stefania; Pepe, Francesca Fulvia; Cogliati, Viola; Sandretti, Francesco; Capici, Serena

Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC)

早期三阴性乳腺癌患者新辅助化疗(NACT)和免疫检查点抑制剂疗效的预测因素

Ardakani, Khashayar Yazdanpanah; Pepe, Francesca Fulvia; Capici, Serena; Clementi, Thoma Dario; Cazzaniga, Marina Elena

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story

CDK4/6抑制剂治疗后HR+/HER2-转移性乳腺癌患者的治疗策略:一个未完待续的故事

Cogliati, Viola; Capici, Serena; Pepe, Francesca Fulvia; di Mauro, Pierluigi; Riva, Francesca; Cicchiello, Federica; Maggioni, Claudia; Cordani, Nicoletta; Cerrito, Maria Grazia; Cazzaniga, Marina Elena

Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows

节拍化疗治疗转移性乳腺癌:临床与临床前数据的亮点与不足

Cazzaniga, Marina Elena; Capici, Serena; Cordani, Nicoletta; Cogliati, Viola; Pepe, Francesca Fulvia; Riva, Francesca; Cerrito, Maria Grazia